Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney

Trial Profile

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Alzheimer's disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms PIOPKD
  • Most Recent Events

    • 18 Aug 2017 Planned primary completion date changed from 1 Oct 2020 to 1 Oct 2019.
    • 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top